Avid Bioservices (CDMO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Avid Bioservices Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2018 and Recent Developments
July 16, 2018 4:05 PM EDT-- Company Records Fiscal Year 2018 Revenue of $53.6 Million --
-- Committed Backlog Increases to $57.8 Million (ASC 605) --
-- Customer Base Expanded and Diversified --
-- Key Appointments Strengthen CDMO Leadership Team --
TUSTIN, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical... More
